HONG KONG – Israel’s Ben-Gurion University of the Negev (BGU) has set up a company to further develop and commercialize its technology into a wearable device for predicting epilepsy-related seizures.

PARIS – Gleamer SAS has secured $8.75 million in series A financing for its CE-marked artificial intelligence (AI) application that automatically detects all types of fracture in radiography. “This funding will allow us to move forward with launching Boneview around the world,” Christian Allouche, CEO and co-founder of Gleamer, told BioWorld.

PERTH, Australia – Chimeric Therapeutics Ltd. has acquired exclusive worldwide rights to develop and commercialize the City of Hope Cancer Center’s chlorotoxin chimeric antigen receptor cell therapy.

In the past 10 years, the advances in understanding the etiology of neurodegenerative diseases have been dramatic. “The development of novel biomarkers and other tools as well are key in aiding diagnostic potential and the ability to track disease progression have been phenomenal,” Isaac Veinbergs, CEO of newly created Libra Therapeutics Inc., told BioWorld.

PERTH, Australia – Sydney-based Chimeric Therapeutics Ltd. has acquired exclusive worldwide rights to develop and commercialize the City of Hope Cancer Center’s chlorotoxin chimeric antigen receptor cell therapy that uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma.

Israeli startup Olive Diagnostics Pvt. Ltd. is aiming to disrupt at-home urinalysis testing with a hands-free, noninvasive, artificial intelligence (AI)-based solution that provides remote diagnostics by detecting urine’s molecular composition. K2, as the device is called, attaches easily to the toilet rim to generate secure, personalized diagnostic data that directly links to a mobile app.

PERTH, Australia – After its initial public offering on the Australian Securities Exchange, soft tissue regeneration company Aroa Biosurgery Ltd. has received new clearances in the U.S. and Europe and is focusing on building up its commercial and manufacturing capacity.

PERTH, Australia – After its initial public offering on the Australian Securities Exchange, soft tissue regeneration company Aroa Biosurgery Ltd. has received new clearances in the U.S. and Europe and is focusing on building up its commercial and manufacturing capacity.

Neuroone Medical Technology Corp.’s thin film, high definition cortical electrode technology, Evo, can record, monitor, ablate, and stimulate brain tissue for up to 30 days, potentially transforming neurosurgical procedures used to treat epilepsy, Parkinson’s disease, chronic pain, and other conditions.

Newly founded Lianbio, with offices in Shanghai and San Francisco, aims to quickly establish a presence in China and Asia with late-stage assets in-licensed from Bridgebio Pharma Inc. and Myokardia Inc. in two deals amounting to $531.5 million and $187.5 million, respectively.